Pharma Journalist -

Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

GSK plc announced today that the US Food and Drug Administration (FDA) has approved its cancer therapy Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and…
Read More...

Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced a multi-year collaboration with Genentech, part of the Roche Group, to discover and optimize novel…
Read More...

Roche announced positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) in patients…
Read More...

GSK plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new prefilled…
Read More...

SAE Media Group unveils the full agenda for AI in Drug Discovery Conference 400 ticket saving ends 7 November 2025. 2026, highlighting the technologies and strategies driving …
Read More...

Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its novel corneal cross-linking therapy, Epioxa™ (Epioxa™ HD / Epioxa™), marking a major…
Read More...

Roche has announced positive phase III results from its IMvigor011 study, showing that Tecentriq® (atezolizumab) significantly improves survival outcomes in patients with…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...